Yu et al. conducted a meta-analysis on twelve studies (7065 cases and 6981 controls) and suggested that RAD51 135G > C might not modify BC risk in non- BRCA1 and BRCA2 mutation carriers9. This evidence concerns the gene BRCA2 and breast cancer.